Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
VNDA Vanda Pharmaceuticals Inc
- Stocks
- Healthcare
- NASDAQ: VNDA
Price (delayed)
$3.95
Market cap
$232.79M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.76
Enterprise value
$128.35M
Vanda is a leading global biopharmaceutical company focused on the development and commercialization of innovative therapies to address high unmet medical needs and improve the lives of patients.
Highlights
The gross profit has increased by 16% YoY
The revenue has increased by 13% YoY
VNDA's debt is up by 13% year-on-year but it is down by 9% since the previous quarter
VNDA's net income has dropped by 134% since the previous quarter
The company's EPS has shrunk by 130% QoQ
Key stats
What are the main financial stats of VNDA
Market
Valuations
Earnings
Shares outstanding
58.93M
Market cap
$232.79M
Enterprise value
$128.35M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.45
Price to sales (P/S)
1.15
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
0.64
Revenue
$201.35M
Gross profit
$189.96M
Operating income
-$72.45M
Net income
-$44.25M
EBIT
-$55.63M
EBITDA
-$47.73M
Free cash flow
-$57.39M
Per share
Balance sheet
Liquidity
EPS
-$0.76
EPS diluted
-$0.76
Free cash flow per share
-$0.98
Book value per share
$8.77
Revenue per share
$3.44
TBVPS
$8.88
Total assets
$631.94M
Total liabilities
$120.52M
Debt
$7.35M
Equity
$511.42M
Working capital
$303.99M
Debt to equity
0.01
Current ratio
3.93
Quick ratio
3.71
Net debt/EBITDA
2.19
Margins
Efficiency
Dividend
EBITDA margin
-23.7%
Gross margin
94.3%
Net margin
-22%
Operating margin
-36%
Return on assets
-6.8%
Return on equity
-8.3%
Return on invested capital
-16.5%
Return on capital employed
-10.5%
Return on sales
-27.6%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
VNDA stock price
How has the Vanda Pharmaceuticals stock price performed over time
Intraday
-6.4%
1 week
-13.57%
1 month
-4.36%
1 year
-21.16%
YTD
-17.54%
QTD
-13.94%
Financial performance
How have Vanda Pharmaceuticals's revenue and profit performed over time
Revenue
$201.35M
Gross profit
$189.96M
Operating income
-$72.45M
Net income
-$44.25M
Gross margin
94.3%
Net margin
-22%
The operating income has plunged by 188% YoY and by 78% from the previous quarter
VNDA's operating margin has shrunk by 154% YoY and by 76% QoQ
VNDA's net income has dropped by 134% since the previous quarter
VNDA's net margin has dropped by 132% since the previous quarter
Price vs fundamentals
How does VNDA's price correlate with its fundamentals
Growth
What is Vanda Pharmaceuticals's growth rate over time
Valuation
What is Vanda Pharmaceuticals stock price valuation
P/E
N/A
P/B
0.45
P/S
1.15
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
0.64
The company's EPS has shrunk by 130% QoQ
VNDA's P/B is 59% below its 5-year quarterly average of 1.1 and 10% below its last 4 quarters average of 0.5
Vanda Pharmaceuticals's equity has decreased by 6% YoY and by 5% QoQ
VNDA's P/S is 48% below its 5-year quarterly average of 2.2 and 23% below its last 4 quarters average of 1.5
The revenue has increased by 13% YoY
Efficiency
How efficient is Vanda Pharmaceuticals business performance
Vanda Pharmaceuticals's ROIC has plunged by 143% from the previous quarter
The company's return on sales has shrunk by 140% QoQ
Vanda Pharmaceuticals's return on equity has shrunk by 137% QoQ
Vanda Pharmaceuticals's ROA has plunged by 134% from the previous quarter
Dividends
What is VNDA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for VNDA.
Financial health
How did Vanda Pharmaceuticals financials performed over time
VNDA's quick ratio is down by 20% YoY and by 12% from the previous quarter
The current ratio is down by 17% year-on-year and by 10% since the previous quarter
VNDA's debt is 99% smaller than its equity
Vanda Pharmaceuticals's debt to equity has plunged by 50% from the previous quarter
VNDA's debt is up by 13% year-on-year but it is down by 9% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.